09-08 Clywedog Therapeutics, Inc. completed the acquisition of Barinthus Biotherapeutics plc from a group of shareholders in a reverse merger transaction. CI
09-07 Barinthus Biotherapeutics plc(NasdaqGM:BRNS) dropped from NASDAQ Composite Index CI
08-06 Barinthus Biotherapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
04-30 Barinthus Biotherapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-22 Barinthus Biotherapeutics plc Appoints Douglas Swirsky as Chief Financial Officer, Effective as of May 1, 2026 CI
04-22 Barinthus Biotherapeutics plc Appoints Douglas Swirsky as Principal Accounting Officer, Effective as of May 1, 2026 CI
03-31 Barinthus Biotherapeutics plc Announces Step Down of Gemma Jones as Principal Accounting Officer, Effective April 30, 2026 CI
03-13 Barinthus Biotherapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2025 CI
12-10 Barinthus Bio announces update on phase 1 Avalon clinical trial of VTP-1000 for the treatment of celiac disease RE
12-10 Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease CI
11-07 Barinthus Biotherapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-09-30 Barinthus Biotherapeutics plc and Clywedog Therapeutics, Inc Announces Executive and Board Changes CI
25-09-28 Clywedog Therapeutics, Inc. executed a letter of intent to acquire Barinthus Biotherapeutics plc from a group of shareholders in a reverse merger transaction. CI
1 day-2.49%
3 months+21.33%
6 months+34.56%
Current year+5.71%
Current year 0.51
Extreme 0.512
0.82
1 year 0.51
Extreme 0.512
1.5
3 years 0.51
Extreme 0.512
5.1
5 years 0.51
Extreme 0.512
14.75
10 years 0.51
Extreme 0.512
17.99
Manager TitleAgeSince
Chief Executive Officer 63 2019-07-31
Director of Finance/CFO 56 2026-04-30
Chief Tech/Sci/R&D Officer 68 2024-05-31
Director TitleAgeSince
Director/Board Member 63 2019-07-31
Chairman 62 2018-09-30
Director/Board Member 45 2019-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/26 Issuer sale

Director

-114,819 0.2913%
9/9/26 Issuer sale

Director

-142,719 0.3621%
9/9/26 Issuer sale

Director

-114,819 0.2913%
Logo Barinthus Biotherapeutics ADR
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
Employees
14
Sector
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Barinthus Biotherapeutics ADR
  1. Stock Market
  2. Stocks
  3. BRNS Stock